The Peptide Stopgap Is Now a Document Under White House Review

On October 14, 2026, the White House Office of Information and Regulatory Affairs received an FDA document titled "Interim Access Policy for Compounding Using Certain Peptides," according to the government's regulatory review site, reginfo.gov. The policy has not been issued, its text is not public, and the filing does not say which peptides it covers.

That is the first official trace of the temporary path for restricted peptides that the Washington Post reported on October 7, which we covered at the time. A plan described by anonymous sources is now a document with a tracking number. What it says is still unknown.

What the filing confirms

The reginfo.gov entry lists the following:

Field	Entry
Title	Interim Access Policy for Compounding Using Certain Peptides
Agency	HHS, Food and Drug Administration
RIN	0910-ZD94
Received	October 14, 2026
Stage	Notice
Review status	Pending review
Economically significant	No
Legal deadline	None

Three things follow from that record and nothing more. The FDA has drafted something it calls an interim access policy. It is a notice, not a proposed or final rule. And it is in the review that significant regulatory actions go through at the Office of Management and Budget before they are published, with no deadline for that review to finish.

What anonymous sources add

The Associated Press reported on October 15, citing two people familiar with the plan who spoke on condition of anonymity, that the policy would let pharmacies temporarily compound some of the most popular peptides. The only one the sources named was BPC-157. The AP described the approach as enforcement discretion, meaning compounding pharmacies would not be targeted for producing certain peptides, rather than a formal listing, which would require rulemaking. HHS did not immediately respond to the AP's request for comment.

Reuters reported the same day that the filing gave no details of the policy, and that the telehealth company Hims & Hers has said it plans to offer peptides if regulations allow.

None of this has been confirmed by HHS or the FDA in a published statement. The covered list, the conditions attached, and whether the policy is limited to state-licensed 503A pharmacies are all open.

What the health secretary said

On October 20, Health Secretary Robert F. Kennedy Jr. said in an interview on Fox News that the administration wants a regulated marketplace for peptides, according to Reuters. "Americans are going to be buying these anyway," he said, describing the goal as making sure that the market is regulated. Reuters reported that the remarks came in response to a question about the proposal sent to the White House.

What has not changed

No peptide has been added to the 503A bulks list. The July recommendations of the Pharmacy Compounding Advisory Committee, which covered BPC-157, KPV, TB-500, MOTS-c, epitalon and semax, are not binding, and we found no proposed or final rule acting on them.

The FDA's category lists are unchanged. The agency's page of substances that may present significant safety risks was last updated April 22, 2026, as of this writing.

No date for the next advisory meeting. The FDA has said it intends to bring five more substances to the committee before the end of February 2027: GHK-Cu, LL-37, dihexa, Melanotan II and PEG-MGF. We found no Federal Register notice setting a date.

Nothing is approved. Enforcement discretion, if that is what the policy turns out to be, is a statement about where the FDA will not act. As the law firm Holland & Knight put it in an October 16 analysis, it does not modify the underlying statutory framework or confer FDA approval on a compounded product. Our explainer on 503A, 503B and research use only sets out the three supply lanes.

The research market is outside it. A compounding policy concerns pharmacies and prescriptions, and nothing published so far suggests it would change the status of material sold online as research chemicals. The FDA's August warning letters to online sellers set out how the agency treats human-use marketing in that channel. We found no new FDA, Department of Justice or Federal Trade Commission peptide enforcement action announced since October 11.

The timeline so far

April 15, 2026. The FDA announces it will remove 12 peptides from Category 2 after their nominations were withdrawn.
July 23 and 24. The advisory committee recommends six of seven peptides for the 503A bulks list, against FDA staff's proposal.
October 7. The Washington Post reports a temporary path is being drafted.
October 14. OIRA receives the interim access policy.
October 15. The AP reports, citing two unnamed sources, that BPC-157 would be covered.
October 20. Kennedy describes the goal as a regulated marketplace.

What to watch

The end of the review. When OIRA concludes it, reginfo.gov will show the outcome, and the FDA would then publish the policy itself, which is the first point at which the covered substances and conditions will be known.

The covered list. Whether it matches the six peptides the committee recommended, includes only some of them, or reaches others such as those removed from Category 2 in April.

The conditions. Trade groups and safety organizations have both proposed adverse-event reporting and quality requirements. Whether any appear in the text is the clearest sign of how the policy is meant to work.

We will cover the primary document when it is published.

Sources:

Nothing here is legal or medical advice. Research use only.

For research use only · Not for human or veterinary use · No research compound discussed here is FDA-approved for any indication